Skip to content
value.today
Cell Source, Inc. logo

Cell Source, Inc.

CLCS
$20 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2024
Net income
$-5 M
SEC filing
Employees
—

Cell Source, Inc. in brief

Cell Source, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its last known market value was $20 M (December 2022); there is no current figure.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cell Source, Inc.

We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology licensed from Yeda Research & Development Company Limited, the commercial arm of the Weizmann Institute of Science in Israel. The current focus of our Research and Development efforts is at the University of Texas MD Anderson Cancer Center in Houston, Texas.

This technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially life-saving treatments have limited effectiveness today because the patient’s immune system rejects them. For example, while HSCT – hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining favor as a treatment of choice. This is still a risky and difficult procedure primarily due to potential conflicts between host and donor immune systems, as well as viral infections that often follow even successful HSCT while the compromised new immune system works to reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression treatments that leave the patient exposed to many dangers by compromising their immune system.

From the company's annual report filed with the US SEC: read the report

Cell Source, Inc. timeline

2 events, 2013–2014
  1. 2013
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. ✎
    Renamed Cell Source, Inc.
    Formerly Ticket To See, Inc..

Events of Cell Source, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$17 M$35 M$52 M$69 M202020212022

World rank over time

▼ down 5,484 places since 2020
2020-01-01: #23874#23,87420202021-01-01: #19823#19,82320212022-01-07: #27619#27,61920222022-12-25: #29358#29,3582022

Rank in USA: #4,355 (Jan 2020) · #3,942 (Jan 2021) · #5,048 (Jan 2022) · #5,282 (Dec 2022)

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue —, net income $-3M—FY17Fiscal year ending Dec 2018: revenue —, net income $-2M—FY18Fiscal year ending Dec 2019: revenue —, net income $-4M—FY19Fiscal year ending Dec 2020: revenue —, net income $-5M—FY20Fiscal year ending Dec 2021: revenue —, net income $-5M—FY21Fiscal year ending Dec 2022: revenue —, net income $-5M—FY22Fiscal year ending Dec 2023: revenue —, net income $-5M—FY23Fiscal year ending Dec 2024: revenue —, net income $-5M—FY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024——$-4M$-5M—
Dec 2023——$-4M$-5M—
Dec 2022——$-4M$-5M—
Dec 2021——$-4M$-5M—
Dec 2020——$-4M$-5M—
Dec 2019——$-4M$-4M—
Dec 2018——$-2M$-2M—
Dec 2017——$-2M$-3M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-3M——$-0.14—
Dec 2023$-2M——$-0.17—
Dec 2022$-3M——$-0.18—
Dec 2021$-3M——$-0.19—
Dec 2020$-3M——$-0.19—
Dec 2019$-3M——$-0.18—
Dec 2018$-2M——$0.09—
Dec 2017$-2M——$-0.12—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Jun 2023: revenue —, net income $-1M—Jun ’23Three months to Sep 2023: revenue —, net income $-1M—Sep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-1M—Dec ’23Three months to Mar 2024: revenue —, net income $-1M—Mar ’24Three months to Jun 2024: revenue —, net income $-1M—Jun ’24Three months to Sep 2024: revenue —, net income $-1M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-0M—Dec ’24Three months to Mar 2025: revenue —, net income $-1M—Mar ’25

Latest quarter to Mar 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.

SEC filings

Official filings of Cell Source, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-4 M
Net income
$-5 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$0 M
Total liabilities
$19 M
Total equity
$-19 M

As of December-2024

Top 1 institutional investors in Cell Source, Inc.#

As of Sep 30, 2026
1 institutions held 3,000 shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 12, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 1 largest institutional investors in Cell Source, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1Planning Project LLC3,000New$0 MNov 12, 2026

Insider trading at Cell Source, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
4
since
Cell Source, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Benzion Abraham FriedmanDirector, 10% ownerOtherindirect+19,440$0.750$15 K4.41 MForm 4
filed Dennis M. BrownDirectorOther+2,976$0.750$2 K114,927Form 4
filed Darlene SoaveDirector, 10% ownerOther+59,507$0.750$45 K174,434Form 4
filed David ZoltyDirectorOtherindirect+4,860$0.750$4 K1.13 MForm 4
filed Dennis M. BrownDirectorOther+3,025$0.750$2 K111,951Form 4
filed David ZoltyDirectorOtherindirect+4,941$0.750$4 K1.12 MForm 4
filed Benzion Abraham FriedmanDirector, 10% ownerOtherindirect+19,672$0.750$15 K4.47 MForm 4
filed Dennis M. BrownDirectorOther+2,992$0.750$2 K108,926Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Cell Source, Inc. scorecard#

Passes 0 of the 6 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.14 vs -0.17Diluted EPS -0.14 in fiscal 2024 against -0.17 the year before (report's currency).
    • ✗Net income higher than five years earlier-$5 M-$5 M in fiscal 2024 against -$4 M in 2019.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2024.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year10.8%Diluted shares up 10.8% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cell Source, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cell Source, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Research and development——1,9381,2738352,457275637554393
Selling, general and administrative——————1,2818169521,098
General and administrative1,9422,6052,1792,6952,6391,175r1,281———
Operating expenses3,8404,3254,1754,0193,6383,805r2,0062,2932,3192,320
Operating income−3,840−4,325−4,175−4,019−3,638−3,805r−2,006−2,293——
Interest expense and finance costs———629457229r−219r17524333r
Other non-operating income (expense)−672−996−992−1,454−922−670r−111−7901,351−184
Income before tax−4,513−5,321−5,168−5,472−4,560−4,475−2,117r−3,323−968−3,083r
Income tax————00—000
Income from continuing operations———————−2,293−2,319−2,320
Net income including minority interests———−5,472−4,560−4,475−2,117———
Net income attributable to shareholders−4,513−5,321−5,168−5,472−4,560−4,475−2,117−3,083−968−2,504
Earnings per share, basic-0.14-0.17-0.18-0.19-0.19-0.180.09r-0.12-0.04-0.10
Earnings per share, diluted-0.14-0.17-0.18-0.19-0.19-0.180.09r-0.12-0.04-0.10
Shares, weighted average (basic)42383533——————
Shares, weighted average (diluted)42383533292828272626
Balance sheet
Cash and cash equivalents752222393242r28193713.76.9
Other current assets1.112231730307.93670135
Current assets———314449——532211214r
Property, plant and equipment————————0.41.3
Total assets28719541031445211566532211215r
Accounts payable1,8891,467680223193135278202219120r
Current liabilities———10,1408,4005,7124,9865,0896,4545,925r
Total liabilities18,82415,80713,04410,1408,4005,8574,9865,0896,4545,973r
Retained earnings−46,180−41,667−36,346−31,178−25,706−21,146−16,670−14,553−11,470−10,503
Shareholders' equity−18,538−15,612−12,634−9,826−7,947−5,742−4,920−4,557−6,243−5,758
Total liabilities and equity28719541031445211566532211215r
Shares outstanding45403634332726252524
Cash-flow statement
Share-based compensation28846378419792r844r−2345115136
Cash from operating activities−2,684−2,348−3,139−3,379−2,775−2,587−2,002−2,288−1,494−2,001r
Debt issued————100120———990
Shares issued—————————71
Cash from financing activities2,7372,1473,2683,2272,9922,5961,6502,6551,4911,988
Change in cash52−200130−1522179.0−352367−3.2−13
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Cell Source, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 5 · Material agreement 1

Cell Source, Inc.: events reported to the SEC
FiledWhat happenedFiling
Auditor changed8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 27, 2025

Acquisitions and funding#

Private share sales · funding history

Private share sales of Cell Source, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$4 MPrivate placement after listing$2 to $10 million48debt, optionsSEC
Sep 2016$9 MPrivate placement after listing$2 to $10 million62equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cell Source, Inc.🇺🇸$20 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cell Source, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cell Source, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cell Source, Inc.? Suggest a correction